Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

Launched by CASE COMPREHENSIVE CANCER CENTER · Apr 3, 2024

Keywords

ClinConnect Summary

This clinical trial, called REIKI, is studying the effects of Reiki therapy on patients with cancer who are receiving care at a specific oncology clinic. Reiki is a gentle, hands-on healing technique that aims to help relieve symptoms related to cancer, such as pain and fatigue. The goal of the study is to see if this therapy can improve the quality of life for patients dealing with these issues.

To participate in the trial, you need to be between 18 and 89 years old, have a confirmed cancer diagnosis, and be experiencing certain symptoms like fatigue. You also need to be able to communicate in English and have access to a computer or mobile device to take part in the study. If you qualify, you can expect to receive Reiki therapy and help researchers learn more about its benefits for cancer patients. It's important to note that certain conditions, such as recent treatments or significant health issues, may prevent you from joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 - 89.
• • Neoplasm diagnosis (i.e., ICD-10 C00 - D49) confirmed in electronic health record (EHR)/Caisis
• • Receiving care at a UH Connor Whole Health Integrative Oncology Clinic.
• • Reporting at least three ESAS symptoms ≥4/10 at baseline screening including fatigue and ≥2 other symptoms on the 9-item questionnaire.
• • Able to speak and understand English.
• • Has an email address, and access to a computer with internet and/or a mobile device with a functioning data plan
• Exclusion Criteria:
• • Significant cognitive impairment that has not been corrected.
• • Significant visual impairment that has not been corrected.
• • Unable to provide informed consent.
• • Active psychosis.
• • Pregnancy.
• • Metastatic disease.
• • Reiki therapy within 3 months of study enrollment
• • Active immunotherapy, chemotherapy, or radiation treatment, or completed within 3 months before study start. Aromatase inhibitors and tamoxifen are exceptions.